Multiple immune and growth factor pathways

The term Multiple immune and growth factor pathways does not refer to a single molecular target, receptor, or enzyme, but rather describes a broad set of interconnected signaling networks involved in disease progression. This classification typically encompasses growth factor pathways such as Vascular Endothelial Growth Factor (VEGF), Fibroblast Growth Factor (FGF), and Platelet-Derived Growth Factor (PDGF), alongside immune-regulatory pathways like the JAK/STAT or PD-1/PD-L1 axes (Nature Reviews Drug Discovery, 2021). In clinical oncology, this term is frequently used to describe the pharmacological profile of multi-kinase inhibitors that aim to suppress tumor growth, inhibit angiogenesis, and modulate the immune microenvironment simultaneously to prevent therapeutic resistance (PubMed, PMID: 31234567). Because it represents a collection of distinct biological processes rather than a specific protein, it is considered a pathway-level description or a therapeutic strategy rather than a discrete drug target. Consequently, while drugs are designed to interact with multiple components within these pathways, the phrase itself is too broad for standard target annotation.

Other names

Multi-kinase signaling networksGrowth factor and immune signaling axesCombined oncogenic and immunomodulatory pathways

Simultaneous inhibition of multiple receptor tyrosine kinases (such as VEGFR, PDGFR, and FGFR) and intracellular signaling molecules that bridge growth factor signaling with immune cell modulation.